Seven Fleet Capital Management LP Raises Stock Holdings in Structure Therapeutics Inc. Sponsored ADR $GPCR

Posted by Brenda Bartman on Aug 27th, 2026

Seven Fleet Capital Management LP raised its stake in shares of Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR – Free Report) by 197.8% during the 2nd quarter, according to its most recent filing with the SEC. The firm owned 26,800 shares of the company’s stock after acquiring an additional 17,800 shares during the period. Seven Fleet Capital Management LP’s holdings in Structure Therapeutics were worth $1,442,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Sterling Capital Management LLC purchased a new position in shares of Structure Therapeutics during the first quarter valued at approximately $28,000. State of Wyoming bought a new stake in Structure Therapeutics in the 2nd quarter worth approximately $28,000. CWM LLC grew its position in Structure Therapeutics by 35.2% in the 4th quarter. CWM LLC now owns 480 shares of the company’s stock worth $33,000 after purchasing an additional 125 shares during the period. Assetmark Inc. raised its stake in Structure Therapeutics by 21.4% during the 1st quarter. Assetmark Inc. now owns 2,544 shares of the company’s stock valued at $123,000 after buying an additional 449 shares during the last quarter. Finally, Police & Firemen s Retirement System of New Jersey bought a new position in shares of Structure Therapeutics during the 4th quarter valued at $127,000. Hedge funds and other institutional investors own 91.78% of the company’s stock.

Structure Therapeutics Price Performance

Shares of Structure Therapeutics stock opened at $49.35 on Thursday. Structure Therapeutics Inc. Sponsored ADR has a 1-year low of $18.26 and a 1-year high of $94.90. The company’s fifty day simple moving average is $50.65 and its 200-day simple moving average is $50.70. The stock has a market capitalization of $3.44 billion, a PE ratio of -49.35 and a beta of -1.43.

Structure Therapeutics (NASDAQ:GPCR – Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.10). As a group, research analysts anticipate that Structure Therapeutics Inc. Sponsored ADR will post -1.84 EPS for the current year.

Wall Street Analyst Weigh In

Several brokerages recently commented on GPCR. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Structure Therapeutics in a report on Friday, July 17th. Citizens Jmp lowered their target price on Structure Therapeutics from $113.00 to $110.00 and set a “market outperform” rating on the stock in a report on Friday, August 7th. Wall Street Zen raised Structure Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Monday, August 17th. HC Wainwright cut their price target on Structure Therapeutics from $100.00 to $70.00 and set a “buy” rating for the company in a research note on Thursday, June 11th. Finally, Canaccord Genuity Group set a $111.00 price target on shares of Structure Therapeutics in a research report on Friday, August 7th. Three research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has issued a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $110.91.

Get Our Latest Report on GPCR

Structure Therapeutics Profile

(Free Report)

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.